Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790036 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 742
- Enrollment target
NCT00790036 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 742 participants.
The verdict
NCT00790036, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 742 participants
- Enrollment target
Study Summary
Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
Interventions
- DRUG Everolimus
- DRUG Everolimus Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 742 participants |
| Start Date | 2009-07-24 |
| Est. Completion | 2016-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790036
The ClinicalTrials.gov registry entry for NCT00790036 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 742 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT00790036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790036 about?
NCT00790036 is a clinical study titled "Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy". Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
What is the current status of trial NCT00790036?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 742 participants. The study started on 2009-07-24. Estimated completion is 2016-06-15.
What interventions are being tested in trial NCT00790036?
The interventions under investigation include: Everolimus (DRUG), Everolimus Placebo (DRUG).
Who is sponsoring clinical trial NCT00790036?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.